CD4 and HIV-1 infection: Because CD4+ T cells are the primary site of HIV-1 infection, replication, and latency (20, 21), the use of ARTs (22) that persist at therapeutic concentrations in lymphoid cells could potentially have a positive impact on long-term treatment outcomes (21).